Recent advances in the regulation of matrix metalloproteinase 2 activation: From basic research to clinical implication (Review)

Oncology Reports

Volumn 9, Issue 3, 2002, Pages 607-611

  Yoshizaki, Tomokazu ^a   Sato, Hiroshi ^b   Furukawa, Mitsuru ^a  

^a Faculty of Medicine   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Head and neck cancer; Metastasis; MMP inhibitor; MMP 2; MT MMP; Prognosis; TIMP 2

Indexed keywords

GELATINASE A; HERMES ANTIGEN; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL; BASEMENT MEMBRANE; BIOLOGICAL MODEL; BIOSYNTHESIS; ENZYME ACTIVATION; FIBROBLAST; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PROGNOSIS; REVIEW;

ANIMALS; ANTIGENS, CD44; BASEMENT MEMBRANE; ENZYME ACTIVATION; FIBROBLASTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; MODELS, BIOLOGICAL; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 0036582737     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.3.607     Document Type: Review

References (57)

1. Fidler IJ and Hart IR: Biologic diversity in metastatic neoplasms-origins and implications. Science 217: 998-1001, 1982.
2. Stetler-Stevenson WG and Yu AE: Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 11: 143-152, 2001. (Pubitemid 32423289)
3. Liotta LA, Steeg P and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991. (Pubitemid 121001258)
4. Liotta LA and Kohn EC: The microenvironment of the tumour-host interface. Nature 411: 375-379, 2001.
5. Kleiner DE and Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 43 (Suppl): S42-S51, 1999. (Pubitemid 29244632)
6. Matrisian LM: The matrix-degrading metalloproteinases. Bioessays 14: 455-463, 1992.
7. Yoshizaki T, Sato H, Maruyama Y, et al: Increased expression of membrane type 1-matrix metalloproteinase in head and neck carcinoma. Cancer 79: 139-144, 1997. (Pubitemid 26425519)
8. Passlick B, Sienel W, Seen-Hibler R, et al: Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 6: 3944-3948, 2000.
9. Horikawa T, Yoshizaki T, Sheen TS, et al: Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 89: 715-723, 2000. (Pubitemid 30658568)
10. Riedel F, Gotte K, Schwalb J, et al: Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol 17: 1099-1105, 2000.
11. Davies B, Waxman J, Wasan H, et al: Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53: 5365-5369, 1993. (Pubitemid 23342150)
12. Mori M, Mimori K, Shiraishi T, et al: Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int J Cancer 74: 316-321, 1997. (Pubitemid 27321802)
13. Afzal S, Lalani EN, Poulsom R, et al: MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Pathol 29: 155-165, 1998. (Pubitemid 28099511)
14. Azzam HS, Arand G, Lippman M, et al: Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 protection. J Natl Cancer Inst 85: 1758-1764, 1993. (Pubitemid 23320847)
15. Sato H, Takino T, Okada Y, et al: A matrix metalloproteinase expressed on the cell surface of invasive tumour cells. Nature 370: 61-65, 1994. (Pubitemid 24216953)
16. Takino T, Sato H, Shinagawa A, et al: Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. J Biol Chem 270: 23013-23020, 1995.
17. Seiki M: Membrane-type matrix metalloproteinase. APMIS 107: 137-143, 1999.
18. Hibbs MS, Hasty KA, Seyer JM, et al: Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. J Biol Chem 260: 2493-2500, 1985. (Pubitemid 15104858)
19. Maatta M, Soini Y, Liakka A, et al: Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 6: 2726-2734, 2000. (Pubitemid 30482111)
20. Nomura H, Sato H, Seiki M, et al: Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 55: 3263-3266, 1995.
21. Tokuraku M, Sato H, Murakami S, et al: Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node. Int J Cancer 64: 355-359, 1995.
22. Yoshizaki T, Maruyama Y, Sato H, et al: Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer 95: 44-50, 2001.
23. Imanishi Y, Fujii M, Tokumaru Y, et al: Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma. Hum Pathol 31: 895-904, 2000.
24. Velasco G, Cal S, Merlos-Suarez A, et al: Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. Cancer Res 60: 877-882, 2000. (Pubitemid 30129519)
25. Collins HM, Morris TM and Watson SA: Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. Br J Cancer 84: 1664-1670, 2001. (Pubitemid 32612499)
26. Shoji A, Sakamato Y, Tsuchiya T, et al: Inhibition of tumor promoter activity toward mouse firoblasts and their in vitro transformation by tissue inhibitor of metalloproteinase-1 (TIMP-1). Carcinogenesis 18: 2093-2100, 1997. (Pubitemid 28134734)
27. Nemeth JA, Rafe A, Steiner M, et al: TIMP-2 growth-stimulatory activity: a concentration- and cell type-specific response in the presence of insulin. Exp Cell Res 224: 110-115, 1996.
28. Guedez L, McMarlin AJ, Kingma DW, et al: Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 158: 1207-1215, 2001. (Pubitemid 32281283)
29. Fassina G, Ferrari N, Brigati C, et al: Tissue inhibitors of metalloproteases: regulation and biological activities. Clin Exp Metastasis 18: 111-120, 2000. (Pubitemid 32165244)
30. Kinoshita T, Sato H, Okada A, et al: TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem 273: 16098-16103, 1998. (Pubitemid 28311379)
31. Imai K, Ohuchi E, Aoki T, et al: Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2. Cancer Res 56: 2707-2710, 1996.
32. Okada A, Bellocq JP, Rouyer N, et al: Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast and head and neck carcinomas. Proc Natl Acad Sci USA 92: 2730-2734, 1995.
33. Bordador LC, Li X, Toole B, et al: Expression of emmprin by oral squamous cell carcinoma. Int J Cancer 85: 347-352, 2000. (Pubitemid 30030407)
34. Dalberg K, Eriksson E, Enberg U, et al: Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer. World J Surg 24: 334-340, 2000. (Pubitemid 30117763)
35. Sun J and Hemler ME: Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 61: 2276-2281, 2001. (Pubitemid 32692059)
36. Zucker S, Hymowitz M, Rollo EE, et al: Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 158: 1921-1928, 2001. (Pubitemid 32545174)
37. Bassi DE, Lopez De Cicco R, Mahloogi H, et al: Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. Proc Natl Acad Sci USA 98: 10326-10331, 2001. (Pubitemid 32803019)
38. Myers EM (ed): Diagnosis. In: Head and Neck Oncology. Little Brown, Boston, pp3-125, 1991.
39. Ohuchi E, Imai K, Fujii Y, et al: Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 272: 2446-2451, 1997. (Pubitemid 27058534)
40. Tews DS and Nissen A: Expression of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors. Inv Metastasis 18: 271-284, 1999. (Pubitemid 30223703)
41. Kajita M, Itoh Y, Chiba T, et al: Membrane-type 1 matrix metallo-proteinase cleaves CD44 and promotes cell migration. J Cell Biol 153: 893-904, 2001. (Pubitemid 34289231)
42. Takahashi K, Eto H and Tanabe KK: Involvement of CD44 in matrix metalloproteinase-2 regulation in human melanoma cells. Int J Cancer 80: 387-395, 1999. (Pubitemid 29019625)
43. Davidson B, Goldberg I, Gotlieb WH, et al: High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 17: 799-808, 1999.
44. O'Charoenrat P, Rhys-Evans PH and Eccles SA: Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 127: 813-820, 2001. (Pubitemid 32619361)
45. Yu Q and Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14: 163-176, 2000. (Pubitemid 30070982)
46. O'Charoenrat P, Modjtahedi H, Rhys-Evans P, et al: Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res 60: 1121-1128, 2000. (Pubitemid 30129555)
47. McCarthy K, Maguire T, McGreal G, et al: High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 84: 44-48, 1999. (Pubitemid 29059107)
48. Kurahara S, Shinohara M, Ikebe T, et al: Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck 21: 627-638, 1999. (Pubitemid 29459868)
49. Visscher DW, Hoyhtya M, Ottosen SK, et al: Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 59: 339-344, 1994. (Pubitemid 24331823)
50. Zeng ZS, Cohen AM, Zhang ZF, et al: Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1: 899-906, 1995.
51. Benassi MS, Gamberi G, Magagnoli G, et al: Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Cancer Res 61: 3610-3618, 2001.
52. Toth M, Bernardo MM, Gervasi DC, et al: Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (membrane type 1)-MMP-dependent activation of pro-MMP-2. J Biol Chem 275: 41415-41423, 2000. (Pubitemid 32054977)
53. Duivenvoorden WC, Hirte HW and Singh G: Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 phase I study. Int J Cancer 91: 857-862, 2001. (Pubitemid 32178657)
54. Nemunaitis J, Poole C, Primrose J, et al: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 4: 1101-1109, 1998. (Pubitemid 28213319)
55. Wojtowicz-Praga S, Torri J, Johnson M, et al: Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 16: 2150-2156, 1998. (Pubitemid 28265052)
56. Zucker S, Cao J and Chen WT: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19: 6642-6650, 2000. (Pubitemid 32197703)
57. Hidalgo M and Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93: 178-193, 2001. (Pubitemid 32166488)